Syndopa CR 125mg Tablet 10pcs

Uses of Syndopa CR 125mg Tablet

• Parkinson's disease

How does Syndopa CR 125mg Tablet work?

• Levodopa: Converts to dopamine in the brain, improving movement control.
• Carbidopa: Prevents the breakdown of levodopa in the body, ensuring more reaches the brain.

Side Effects of Syndopa CR 125mg Tablet

Common side effects include dyskinesia, nausea, hallucinations, confusion, dizziness, and dry mouth. Severe side effects can include neuroleptic malignant syndrome, orthostatic hypotension, and cardiac irregularities.

Quick Suggestions:

• Adhere to the prescribed schedule for consistent medication levels in the body.
• Rise slowly from sitting or lying positions to avoid dizziness or lightheadedness.
• Be cautious with activities requiring alertness, such as driving, due to potential drowsiness.

Indication of Syndopa CR 125mg Tablet

Levodopa-Carbidopa prolonged-release tablets are indicated for the treatment of idiopathic Parkinson's disease, particularly to reduce "off" periods in patients who have been previously treated with levodopa/decarboxylase inhibitors or with levodopa alone and have experienced motor fluctuations.

Pharmacology

According to current data, symptoms of Parkinson's disease are linked to dopamine depletion in the corpus striatum. Dopamine's metabolic precursor, levodopa, crosses the blood-brain barrier and is likely converted to dopamine in the brain. Carbidopa prevents peripheral levodopa from being decarboxylated.
Because carbidopa's decarboxylase inhibitory effect is limited to extracerebral tissues, combining it with levodopa increases the amount of levodopa accessible for delivery to the brain.

Dosage & Administration of Syndopa CR 125mg Tablet

Dosage For patients currently treated with conventional levodopa/decarboxylase inhibitor combinations, the dosage with Levodopa-Carbidopa prolonged-release tablets should initially provide no more than approximately 10% more levodopa per day, with the dosing interval extended by 30 to 50%, ranging from 4 to 12 hours. Dosages up to 30% more levodopa per day may be necessary. Conversion guidelines from conventional to prolonged-release tablets are provided.

Administration Patients currently on levodopa alone should discontinue levodopa at least eight hours before starting the CR tablet. For those with mild to moderate disease not previously treated with levodopa, the initial dose is one CR tablet twice daily, not exceeding 600 mg of levodopa per day.

Interaction

Caution is needed when administering Levodopa-Carbidopa with antihypertensive agents, antidepressants, anticholinergics, iron supplements, and other drugs that may interact with levodopa or carbidopa.

Contraindications

Levodopa-Carbidopa prolonged-release tablets are contraindicated in patients with hypersensitivity to any component, narrow-angle glaucoma, and those treated with non-selective monoamine oxidase inhibitors. It is also contraindicated in patients with undiagnosed skin lesions or a history of melanoma.

Pregnancy & Lactation

There is insufficient data on the use of Levodopa-Carbidopa in pregnancy. It should not be used during pregnancy or lactation.

Precautions & Warnings

Care is required when administering to patients with severe cardiovascular or pulmonary disease, peptic ulcer history, or convulsions. Levodopa has been associated with sleepiness and sudden sleep onset; patients must be cautious about driving or operating machinery. Behavioral monitoring is recommended due to potential impulse control disorders.

Storage Conditions:

Store in a cold, dry, and light-protected location.